Seven Grand Managers’s Apogee Therapeutics APGE Stock Holding History

Seven Grand Managers’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.3M	Hold	100,000	–	–	0.53%	43
2026 Q1	$8.42M	Buy	100,000 +50,000	+100%	+$3.63M	0.56%	38
2025 Q4	$3.77M	Buy	+50,000	New	+$3.15M	0.29%	79
2023 Q4	–	Sell	-48,198	Closed	-$1.03M	–	36
2023 Q3	$1.03M	Buy	+48,198	New	+$1.06M	1.37%	18

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Seven Grand Managers's APGE Position: Q2 2026 in Review

Seven Grand Managers held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 100,000 shares worth $13.3M. The position accounts for 0.53% of the portfolio, ranked #43.

Seven Grand Managers first reported a position in APGE in Q3 2023 and has held it in 4 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Seven Grand Managers held 100,000 shares of Apogee Therapeutics worth $13.3M as of Q2 2026.
Seven Grand Managers left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up 0.53% of Seven Grand Managers's portfolio in Q2 2026, its #43 holding.
Seven Grand Managers first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 4 quarters since.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.